A Clinical Trial of Envafolimab Combined With Lenvatinib for Kidney Cancer With Liver Spread
Status:
NOT_YET_RECRUITING
Trial end date:
2028-05-30
Target enrollment:
Participant gender:
Summary
This is an open-label, single-arm, prospective, multicenter clinical study designed to evaluate the efficacy and safety of envafolimab in combination with lenvatinib for the treatment of patients with clear cell renal cell carcinoma (ccRCC) accompanied by liver metastases. The Department of Urology at Fudan University Shanghai Cancer Center serves as the primary research center.